CG Oncology, Inc. CGON
Super Investor & Insider
| Data filing | Data op. | Insider | Ruolo | Tipo | Prezzo | Quantità | Valore |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | 2026-06-15 | Mulay James | Dir | Vendita | $60.12 | -654 | $39,318 |
| 2026-06-16 | 2026-06-15 | Mulay James | Dir | Vendita | $60.12 | -1,310 | $78,757 |
| 2026-06-05 | 2026-06-04 | Post Leonard E | Dir | Vendita | $54.50 | -1,000 | $54,500 |
| 2026-04-20 | 2026-04-17 | Mulay James | Dir | Vendita | $73.01 | -15,600 | $1.1M |
| 2026-03-17 | 2026-03-16 | Mulay James | Dir | Vendita | $63.50 | -654 | $41,529 |
| 2026-03-17 | 2026-03-16 | Mulay James | Dir | Vendita | $63.50 | -1,310 | $83,185 |
| 2026-01-13 | 2026-01-09 | Mulay James | Dir | Vendita | $44.16 | -654 | $28,881 |
| 2026-01-13 | 2026-01-09 | Mulay James | Dir | Vendita | $52.99 | -10,491 | $555,918 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesical…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees142
TickerCGON
Statistics
Market Cap$5.45B
Revenue (TTM)$4.0M
Net Income-$161.0M
Net Margin-3985.0%
EPS$-2.08
P/E-27.72
P/S985.69
P/B4.57
EV/EBITDA-18.48
ROE-20.8%
Dividend Yield—
Price$61.91
Data: Twelve Data · Revenue = mcap / P/S